Pembrolizumab (KEYTRUDA (R)) significantly prolonged Overall Survival and progression-free Survival in Patients with metastatic non-small cell Lung Cancer without Squamous Epithelium-Histology-MedSci.cn

Pembrolizumab (KEYTRUDA (R)) significantly prolonged Overall Survival and progression-free Survival in Patients with metastatic non-small cell Lung Cancer without Squamous Epithelium-Histology

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2018; 41 (4): 243

科室
- - 订阅+
  - 更多科室
工具
服务